ClinicalTrials.gg
CompletedNCT00645242Updated Jul 16, 2021

A Study Of Diflucan In Children With Ringworm Of The Scalp

A Phase 3 interventional study of fluconazole in Tinea Capitis, sponsored by Pfizer. Completed at 31 sites in 2 countries. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Not applicable
Ages
3 Years to 12 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of fluconazole for the treatment of tinea capitis in pediatric patients aged 3 to 12 years.

02

Conditions studied

  • Tinea Capitis
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients (aged 3-12 years)
  • Clinical diagnosis of tinea capitis
  • Direct microscopy (KOH) positive for fungal elements within or outside hair shaft

Exclusion criteria

Exclusion Criteria:

  • Negative baseline KOH
  • Liver disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
185 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: fluconazole

Interventions

  • Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment

06

What researchers measure

Primary outcomes

  1. Combined clinical and mycological outcome at Week 6

    Time frame: Week 6

Secondary outcomes

  1. Clinical outcome based on signs and symptoms at Weeks 3, 6, and 10

    Time frame: Weeks 3, 6, and 10

  2. Combined clinical and mycological outcome at Weeks 3 and 10

    Time frame: Weeks 3 and 10

  3. Mycological outcome based on culture results at Weeks 3, 6, and 10

    Time frame: Weeks 3, 6, and 10

  4. Culture results at Weeks 3, 6, and 10

    Time frame: Weeks 3, 6, and 10

07

Study locations

31 sites
  • Pfizer Investigational Site
    Montgomery, Alabama 36116, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    San Diego, California 92123, United States
  • Pfizer Investigational Site
    Miami, Florida 33156-7712, United States
  • Pfizer Investigational Site
    Miami, Florida 33156, United States
  • Pfizer Investigational Site
    Martinez, Georgia 30907, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60630, United States
  • Pfizer Investigational Site
    Evanston, Illinois 60202, United States
  • Pfizer Investigational Site
    Gretna, Louisiana 70056, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70119, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71105, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48201, United States
  • Pfizer Investigational Site
    Fridley, Minnesota 55432, United States
  • Pfizer Investigational Site
    Bridgeton, Missouri 63044, United States
  • Pfizer Investigational Site
    Brooklyn, New York 11203-2098, United States
  • Pfizer Investigational Site
    Garner, North Carolina 27529, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27609, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44106, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43205, United States
  • Pfizer Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37927, United States
  • Pfizer Investigational Site
    Murfreesboro, Tennessee 37130, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37215, United States
  • Pfizer Investigational Site
    Houston, Texas 77056, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78205, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78224, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Norfolk, Virginia 23507, United States
  • Pfizer Investigational Site
    Carolina, 00985, Puerto Rico
  • Pfizer Investigational Site
    Ponce, 00717-2115, Puerto Rico
  • Pfizer Investigational Site
    Ponce, 99717, Puerto Rico
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a completion of Mar 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2008
First posted
Mar 27, 2008
Start
Nov 2002
CompletionActual
Mar 2003
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00645242
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
Nov 2002
Completion
Mar 2003
Last update
Jul 16, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluconazole

Start the discussion